#### TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES

#### INDEX TO UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2009

	<u>Page</u>
ACCOUNTANTS' REVIEW REPORT	1
BALANCE SHEETS	2
STATEMENTS OF OPERATIONS	3
STATEMENTS OF CASH FLOWS	4-5
NOTES TO FINANCIAL STATEMENTS	6-21



Brightman Almagor Zohar 1 Azrieli Center Tel Aviv 67021 P.O.B. 16593, Tel Aviv 61164 Israel

Tel: +972 (3) 608 5555 Fax: +972 (3) 609 4022 info@deloitte.co.il www.deloitte.com

#### Review Report of the Independent Auditor to the shareholders of Tower Semiconductor Ltd.

#### Introduction

We have reviewed the accompanying financial information of Tower Semiconductor Ltd. and subsidiaries (hereafter- "the Company") which includes the condensed consolidated balance sheet as of September 30, 2009, the condensed consolidated statements of operations for the nine and three months period then ended and condensed consolidated statements of cash flows for the nine months period then ended. The board of directors and management are responsible for the preparation and presentation of this interim financial information in accordance with APB 28 "Interim Financial Reporting". Our responsibility is to express a conclusion on this interim financial information based on our review.

#### Scope of Review

We conducted our review in accordance with Review Standard 1 of the Institute of Certified Public Accountants in Israel "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the standards of Public Company Accounting Oversight Board (United States) and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

#### Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the above financial information is not prepared, in all material respects, in accordance with APB 28 "Interim Financial Reporting".

As discussed in Note 2 to the financial statements, the Company changed its method of accounting for inventory costing.

Brightness Almager Zoher & Co.

**Certified Public Accountants** 

A Member Firm of Deloitte Touche Tohmatsu

Tel Aviv, Israel November 13, 2009

### TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS

(dollars in thousands)

		Se	As of ptember 30,	As of December 31,		
	Note		2009		2008	
		(u	naudited)			
ASSETS						
CURRENT ASSETS  Cash and cash equivalents  Trade accounts receivable:		\$	51,708	\$	34,905	
Related parties			162		2,379	
Others			41,959		43,481	
Other receivables			3,418		2,320	
Inventories	2		28,746		40,899	
Other current assets  Total current assets			7,519		7,657	
Total current assets			133,312		131,041	
LONG-TERM INVESTMENTS			29,579		29,499	
PROPERTY AND EQUIPMENT, NET			388,234		449,697	
INTANGIBLE ASSETS, NET			70,983		81,034	
GOODWILL			7,000		7,000	
OTHER ASSETS , NET			8,282	<u></u>	8,802	
TOTAL ASSETS		\$	637,590	<b>\$</b>	707,673	
LIABILITIES AND SHAREHOLDERS' EQUITY						
CURRENT LIABILITIES		_				
Current maturities of convertible debenture		\$	4 440	\$	8,330	
Short-term bank loan Trade accounts payable			4,440 39,180		7,000 49,462	
Deferred revenue and short-term customers' advances			4,100		6,634	
Other current liabilities			32,228		35,202	
Total current liabilities			79,948		106,628	
LONG-TERM LOANS FROM BANKS	4		184,687		222,989	
DEBENTURES	4		231,868		208,512	
LONG-TERM CUSTOMERS' ADVANCES			12,412		11,138	
OTHER LONG-TERM LIABILITIES	4		55,020		45,959	
Total liabilities			563,935		595,226	
SHAREHOLDERS' EQUITY	5	<u></u>	73,655	<u></u>	112,447	
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY		\$	637,590	\$	707,673	

See notes to consolidated financial statements.

### TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS

(dollars in thousands, except share data and per share data)

	Nine months ended September 30,				ended 80,		
	2009 2008			2009		2008	
	(unaudited)				(unaudited)		
REVENUES	\$ 198,1	96 \$	174,206	\$	79,570	\$	58,527
COST OF REVENUES	231,2	48	210,443	_	84,915	_	71,136
GROSS LOSS	(33,0	52)	(36,237)		(5,345)		(12,609)
OPERATING COSTS AND EXPENSES							
Research and development	16,3	64	9,690		6,057		3,500
Marketing, general and administrative	21,9	13	22,685		8,025		7,728
Write-off of in-process research and development	-	-	2,300				2,300
Merger related costs Fixed assets impairment	-	-	520 120,538				520 120,538
ricu assets impairment	38,2	<del></del>	155,733		14,082	-	134,586
OPERATING LOSS	(71,3	29)	(191,970)		(19,427)	_	(147,195)
FINANCING EXPENSE, NET	(27,0	32)	(20,374)		(16,758)		(4,763)
GAIN ON DEBT RESTRUCTURING	-	-	130,698				130,698
OTHER INCOME (EXPENSE), NET	2,	163	(638)	_	1,704	_	(109)
LOSS BEFORE INCOME TAX BENEFIT	(96,1	98)	(82,284)		(34,481)		(21,369)
INCOME TAX BENEFIT	7,1	50_		_	4,240	-	
LOSS FOR THE PERIOD	\$ (89,0	<u>48)</u> \$	(82,284)	<b>\$</b> _	(30,241)	\$ <sub>_</sub>	(21,369)
BASIC AND DILUTED LOSS PER ORDINARY SHARE							
Loss per share	\$(0.	<u>55)</u> \$	(0.65)	\$_	(0.18)	\$	(0.17)
Weighted average number of ordinary							
shares outstanding - in thousands	162,4	<u>47</u>	126,356	_	167,200		129,479

See notes to consolidated financial statements.

### TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS

(dollars in thousands)

Nine months ended September 30,

	September 30,			
		2009		2008
CACH ELOWC OPERATING ACTIVITIES		(unau	dited)	
CASH FLOWS - OPERATING ACTIVITIES				
Loss for the period	\$	(89,048)	\$	(82,284)
Adjustments to reconcile loss for the period				
to net cash provided by operating activities:				
Income and expense items not involving cash flows:				
Gain on debt restructuring				(130,698)
Depreciation and amortization		105,213		109,926
Effect of indexation, translation and fair value measurement on debt		(2,587)		2,324
Fixed assets impairment				120,538
Other expense (income), net		(2,163)		638
Write-off of in-process research and development				2,300
Changes in assets and liabilities:				
Trade accounts receivable		3,739		6,380
Other receivables and other current assets		(695)		3,256
Inventories		12,153		(10,520)
Trade accounts payable		(7,566)		(3,325)
Deferred revenue and customers' advances		(1,039)		(9,423)
Other current liabilities		(3,371)		821
Other long-term liabilities		(6,687)		1,004
Net cash provided by operating activities		7,949		10,937
CASH FLOWS - INVESTING ACTIVITIES				
Investments in property and equipment		(18,199)		(70,632)
Acquisition of subsidiary consolidated for the first time (a)				2,765
Investments in other assets and intangible assets				(658)
Long-term investments		(1,022)		
Net cash used in investing activities		(19,221)		(68,525)
CASH FLOWS - FINANCING ACTIVITIES				
Proceeds from long-term loans				32,000
Proceeds on account of capital notes		20,000		20,000
Proceeds from issuance of ordinary shares and warrants, net		22,160		20,000
Proceeds from exercise of share options		20		
Proceeds from issuance of debentures and warrants, net				1,440
Short-term loan from Bank		(2,560)		7,000
Repayment of debenture		(8,254)		(8,179)
Debts repayment		(3,216)		(1,000)
Net cash provided by financing activities		28,150		51,261
Effect of foreign exchange rate change		(75)		
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		16 902		(6 227)
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD		16,803 34,905		(6,327) 44,536
CASH AND CASH EQUIVALENTS - END OF PERIOD	<u> </u>	51,708	\$	38,209
CHAIRING CHAIR EQUITIBLE TO THE OF TERROR	Ψ	51,700	Ψ	50,207

### TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS

(dollars in thousands)

Nine months ende	ed
September 30,	
009	20
(unaudited)	

	(unau	uneu)	
\$	885	\$	14,377
\$	3,987	\$	1,913
===		===	
\$	404	\$	3,907
\$	3,829	\$	
\$		\$	95,071
\$		\$	46,744
\$	13,752	\$	12,853
\$	1,173	\$	1,237
		Sen	As of tember 19,
		БСР	2008
		-	
		\$	(4,270)
			83,130
			17,100
			61,900
			66
			(108,600)
			(108,600) (11,074)
			(108,600) (11,074) 8,807
			(108,600) (11,074)
			(108,600) (11,074) 8,807
			(108,600) (11,074) 8,807 47,059
			(108,600) (11,074) 8,807 47,059
	\$ \$ \$ \$	\$ 885 \$ 3,987 \$ 404 \$ 3,829 \$ \$	\$ 3,987 \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$

See notes to consolidated financial statements.

(dollars in thousands, except share data and per share data)

#### NOTE 1 - GENERAL

#### A. Basis for Presentation

(1) The consolidated financial statements of Tower Semiconductor Ltd ("Tower") include the financial statements of Tower and its wholly-owned subsidiaries, Tower Semiconductor USA, a marketing and sales subsidiary in the United States and Jazz Technologies ("Jazz"), a leading independent wafer foundry focused on Analog-Intensive Mixed -Signal (AIMS) process technologies based in Newport Beach, California. Tower and its wholly owned subsidiaries are referred to as the "Company". References to the "Company" for dates prior to the merger of Tower and Jazz on September 19, 2008 (the "Jazz Merger"), shall exclude Jazz.

The Company's consolidated financial statements include the results of Jazz for the nine months ended September 30, 2009 and for the period between September 19, 2008 and September 30, 2008. The Company's consolidated financial statements include Jazz's balance sheet as of September 30, 2009 and December 31, 2008. The Company's consolidated financial statements are presented after elimination of inter-company transactions and balances. The unaudited condensed interim consolidated financial statements as of September 30, 2009 of the Company should be read in conjunction with the audited consolidated financial statements of the Company as of December 31, 2008 and for the year then ended, including the notes thereto.

In the opinion of management, the interim financial statements include all adjustments necessary for a fair presentation of the financial position and results of operations as of the date and for the interim periods presented. The results of operations for the interim periods are not necessarily indicative of the results to be expected on a full-year basis.

(2) The interim financial statements are presented in accordance with U.S. generally accepted accounting principles ("US GAAP").

#### (3) Initial Adoption of New Standards

#### Accounting Standards Codification ("ASC") 815-40 (EITF 07-5)

In June 2008, the FASB Emerging Issues Task Force reached a consensus on EITF Issue No. 07-5, "Determining Whether an Instrument (or an Embedded Feature) is Indexed to an Entity's Own Stock". The consensus is an amendment to ASC 815-40 Contract in Entity's Own Equity.

(dollars in thousands, except share data and per share data)

#### NOTE 1 - GENERAL (cont.)

#### A. Basis for Presentation (cont.)

#### (3) Initial Adoption of New Standards (cont.)

Accounting Standards Codification ("ASC") 815-40 (EITF 07-5) (cont.)

The Company applies this consensus effective January 1, 2009. The Company identified several instruments that are affected by the consensus all of which were, before the adoption of the consensus, classified in equity and upon the adoption were reclassified from equity to liabilities. These instruments include warrants and a previously bifurcated conversion option, with either an anti-dilution feature or with an exercise price denominated in NIS. At the date of adoption and in accordance with transition provisions of the consensus, the Company measured those instruments at fair value. The difference between the fair values and the amount previously recorded in equity was recognized as an adjustment to the opening balance of retained earnings.

The effect of the adoption on equity retained earnings is as follows:

	Janua	ry 1, 2009
Additional paid in capital	\$	(14,065)
Retained earnings		12,800
Fair value reclassified to liability	\$	(1,265)

The effect of the adoption on the Company's consolidated results of operations and net loss for the nine and three months ended September 30, 2009 was \$13,944 and \$11,888 respectively.

(dollars in thousands, except share data and per share data)

#### NOTE 1 - GENERAL (cont.)

#### A. Basis for Presentation (cont.)

#### (3) Initial Adoption of New Standards (cont.)

#### ASC 470-20-15 (FSP APB 14-1)

Effective January 1, 2009, the Company applies the amendment to ASC 470-20-15 (FSP No. APB 14-1), "Accounting for Convertible Debt Instruments that may be Settled in Cash upon Conversion (Including Partial Cash Settlement)". The provision of the amendment applies to any convertible debt instrument that may be wholly or partially settled in cash and requires the separation of the debt and equity components of cash-settleable convertibles at the date of issuance. The amendment is effective for the 8% convertible debt issued by Jazz due in 2011. Following the Jazz Merger, as part of the purchase method, Jazz was required to fair value its convertible debt instrument. As a result, a new basis was determined for the convertible notes of \$108.600. The debt discount was \$19.600. Upon adoption of the amendment, the Company evaluated the equity component as of the date of the Jazz Merger and determined that it is immaterial. As such, the Company expects no impact on the Company's consolidated results of operations or financial position resulting from the adoption of this amendment for periods following the Jazz Merger.

#### Amendment to ASC 815 (SFAS No. 161)

Effective January 1, 2009, the Company adopted the disclosure requirements in the amendment to ASC 815 (added by SFAS No. 161), "Disclosures about Derivative Instruments and Hedging Activities", which expands disclosures but does not change accounting for derivative instruments and hedging activities. The adoption of the amendment did not have any impact on the consolidated results of operations or financial position of the Company.

#### ASC 825-10-50 and 270-10-50 (FSP FAS 107-1 and APB 28-1)

In April 2009, the FASB amended the disclosure requirements in section 825-10-50 and 270-10-50 of the ASC through the issuance of FASB staff position (FSP FAS 107-1 and APB 28-1), "Interim Disclosures about Fair Value of Financial Instruments". This amendment applies to all financial instruments within the scope of ASC 825 held by publicly traded companies, as defined by ASC 270-20 (Interim Reporting) and are effective for interim reporting periods ending after June 15, 2009, with early adoption permitted for periods ending after March 15, 2009.

(dollars in thousands, except share data and per share data)

#### NOTE 1 - GENERAL (cont.)

#### A. Basis for Presentation (cont.)

#### (3) Initial Adoption of New Standards (cont.)

ASC 825-10-50 and 270-10-50 (FSP FAS 107-1 and APB 28-1) (cont.)

ASC 825-10 (Financial Instruments) requires fair value disclosures for any financial instruments that are not currently reflected on the balance sheet of companies at fair value. Prior to issuing of this amendment, fair values for these assets and liabilities were only disclosed once a year. The amendment now requires these disclosures on a quarterly basis, providing qualitative and quantitative information about fair value estimates for all those financial instruments not measured on the balance sheet at fair value, see Note 4.

#### ASC 320-10-65 (FSP FAS 115-2 and FAS 124-2)

In April 2009, the FASB issued an amendment to ASC 320-10-65 (Investments - Debt and Equity Securities) through the issuance of FASB staff position 115-2 and 124-2, "Recognition and Presentation of Other-Than-Temporary Impairments" ("OTTI") for investment in debt securities. This amendment applies to all entities and is effective for interim and annual reporting periods ending after June 15, 2009, with early adoption permitted for periods ending after March 15, 2009.

Under the amendment, the primary change to the OTTI model for debt securities is the change in focus from an entity's intent and ability to hold a security until recovery. Instead, an OTTI is triggered if (1) an entity has the intent to sell the security, (2) it is more likely than not that it will be required to sell the security before recovery, or (3) it does not expect to recover the entire amortized cost basis of the security. In addition, the amendment changes the presentation of an OTTI in the income statement if the only reason for recognition is a credit loss (i.e., the entity does not expect to recover its entire amortized cost basis). That is, if the entity has the intent to sell the security or it is more likely than not that it will be required to sell the security, the entire impairment (amortized cost basis over fair value) will be recognized in earnings.

(dollars in thousands, except share data and per share data)

#### NOTE 1 - GENERAL (cont.)

#### A. Basis for Presentation (cont.)

#### (3) Initial Adoption of New Standards (cont.)

#### ASC 320-10-65 (FSP FAS 115-2 and FAS 124-2) (cont.)

However, if the entity does not intend to sell the security and it is not more likely than not that the entity will be required to sell the security, but the security has suffered a credit loss, then the impairment charge will be separated into the credit loss component, which is recorded in earnings, and the remainder of the impairment charge, which is recorded in other comprehensive income. The adoption of this standard did not have any impact on the consolidated results of operations or financial position of the Company.

#### Amendment to ASC 820 (FSP FAS 157-4)

In April 2009, the FASB issued an amendment to ASC 820 through the issuance of FASB staff position 157-4, "Determining Fair Value When the Volume and Level of Activity for the Asset or Liability Have Significantly Decreased and Identifying Transactions that are Not Orderly". This amendment applies to all assets and liabilities within the scope of accounting pronouncements that require or permit fair value measurements, except as discussed in ASC 820-10-15-2. The amendment is effective for interim and annual reporting periods ending after June 15, 2009, and shall be applied prospectively.

ASC 820-35-51 relates to determining fair values when there is no active market or where the price inputs being used represent distressed sales. It reaffirms the objective of fair value measurement, as stated in ASC 820, to reflect how much an asset would be sold for in an orderly transaction (as opposed to a distressed or forced transaction) at the date of the financial statements under current market conditions. Specifically, it reaffirms the need to use judgment to ascertain if a formerly active market has become inactive and in determining fair values when markets have become inactive.

The amendment provides guidance on (1) estimating the fair value of an asset or liability (financial and nonfinancial) when the volume and level of activity for the asset or liability have significantly decreased and (2) identifying transactions that are not orderly. The adoption of this standard did not have any impact on the consolidated results of operations or financial position of the Company.

(dollars in thousands, except share data and per share data)

#### NOTE 1 - GENERAL (cont.)

#### A. Basis for Presentation (cont.)

#### (3) Initial Adoption of New Standards (cont.)

ASC 855 (SFAS 165)

In May 2009, the FASB issued ASC 855 (SFAS No. 165), "Subsequent Events". ASC 855 establishes general standards of accounting for, and disclosure of, events that occur after the balance sheet date but before financial statements are issued or are available to be issued. In particular, this statement sets forth: (1) the period after the balance sheet date during which management of a reporting entity should evaluate events or transactions that may occur for potential recognition or disclosure in the financial statements, (2) the circumstances under which an entity should recognize events or transactions occurring after the balance sheet date in its financial statements and (3) the disclosures that an entity should make about events or transactions that occurred after the balance sheet date. ASC 855 is effective for the interim or annual financial periods ending after June 15, 2009. The adoption of this standard did not have any impact on the consolidated results of operations or financial position of the Company.

#### (4) Recently Issued Accounting Standards

#### **SFAS 166**

In June 2009 the FASB issued SFAS No.166 "Accounting for Transfers of Financial Assets" (not yet codified). This SFAS is a revision to ASC 860 Transfer and Servicing (formerly Statement No. 140, "Accounting for Transfers and Servicing of Financial Assets and Extinguishments of Liabilities"), and will require more information about transfers of financial assets, including securitization transactions, and continued exposure to the risks related to transferred financial assets. It eliminates the concept of a "qualifying special-purpose entity," changes the requirements for derecognizing financial assets, and requires additional disclosures. SFAS No. 166 enhances information reported to users of financial statements by providing greater transparency about transfers of financial assets and a company's continuing involvement in transferred financial assets. SFAS No. 166 will be effective at the start of a company's first fiscal year beginning after November 15, 2009. The adoption of this standard is not expected to have a material impact on the Company's consolidated financial statements.

(dollars in thousands, except share data and per share data)

#### NOTE 1 - GENERAL (cont.)

#### A. Basis for Presentation (cont.)

#### (4) Recently Issued Accounting Standards (cont.)

#### **SFAS 167**

In June 2009, the FASB issued SFAS No. 167 "Amendments to ASC 810 Consolidation (formerly FASB Interpretation No. 46(R))" (not yet codified) ("SAFS No. 167"), which changes the way entities account for securitizations and special-purpose entities. SAFS No. 167 is a revision to ASC 810, and changes how a company determines when an entity that is insufficiently capitalized or is not controlled through voting (or similar rights) should be consolidated. The determination of whether a company is required to consolidate an entity is based on, among other things, an entity's purpose and design and a company's ability to direct the activities of the entity that most significantly impact the entity's economic performance. This SFAS will require a company to provide additional disclosures about its involvement with variable interest entities and any significant changes in risk exposure due to that involvement. A company will be required to disclose how its involvement with a variable interest entity affects the company's financial statements. SFAS No. 167 will be effective at the start of a company's first fiscal year beginning after November 15, 2009. The adoption of this standard is not expected to have material impact on the Company's consolidated financial statements.

#### ASC 105 (SFAS 168)

In June 2009, the FASB issued ASC 105, "The FASB Accounting Standards Codification and the Hierarchy of Generally Accepted Accounting Principles". ASC 105 establishes the "FASB Accounting Standards Codification" ("Codification"), and was officially launched on July 1, 2009, for the purpose of serving as the source of authoritative U.S. generally accepted accounting principles ("GAAP") recognized by the FASB to be applied by nongovernmental entities. Rules and interpretive releases of the Securities and Exchange Commission ("SEC") under authority of federal securities laws are also sources of authoritative U.S. GAAP for SEC registrants. The subsequent issuances of new standards will be in the form of Accounting Standards Updates that will be included in the Codification. In general, the Codification is not expected to change U.S. GAAP. All other accounting literature excluded from the Codification will be considered

(dollars in thousands, except share data and per share data)

#### NOTE 1 - GENERAL (cont.)

#### A. Basis for Presentation (cont.)

#### (4) Recently Issued Accounting Standards (cont.)

ASC 105 (SFAS 168) (cont.)

non-authoritative. ASC 105 is effective for financial statements issued for interim and annual periods ending after September 15, 2009. Effective September 30, 2009, all references made to GAAP in our consolidated financial statements include the new Codification numbering system along with original references.

#### ASU 2009-13

In October 2009, the FASB issued "Accounting Standards Update ("ASU") 2009-13 Multiple Deliverable Revenue Arrangements a consensus of EITF" (formerly topic 08-1) an amendment to ASC 605-25. The update provides amendments to the criteria in Subtopic 605-25 for separating consideration in multiple-deliverable arrangements. The amendments in this update establish a selling price hierarchy for determining the selling price of a deliverable. The selling price used for each deliverable will be based on vendor-specific objective evidence if available, third-party evidence if vendor-specific objective evidence is not available, or estimated selling price if neither vendor-specific objective evidence nor third-party evidence is available. The amendments in this update also will replace the term "fair value" in the revenue allocation guidance with the term "selling price" in order to clarify that the allocation of revenue is based on entity-specific assumptions rather than assumptions of a marketplace participant.

The amendments will also eliminate the residual method of allocation and require that arrangement consideration be allocated at the inception of the arrangement to all deliverables using the relative selling price method. The relative selling price method allocates any discount in the arrangement proportionally to each deliverable on the basis of each deliverable's selling price.

The update will be effective for revenue arrangements entered into or modified in fiscal year beginning on or after June 15, 2010 with earlier adoption permitted. The adoption of this standard is not expected to have material impact on the Company's consolidated financial statements.

(5) Certain amounts in prior periods' financial statements have been reclassified in order to conform to 2009 presentation.

(dollars in thousands, except share data and per share data)

#### NOTE 1 - GENERAL (cont.)

#### B. Financing of the Company's Debt Obligations and Other Liabilities

During the past years, the Company has experienced significant recurring losses and an increasing accumulated deficit. The Company has been working in various ways to mitigate these financial losses and has been successful in increasing its customer base, increasing its sales, improving its EBITDA and cash flow from operations, increasing its installed capacity level, raising funds, restructuring its debt and modifying its organizational structure to better address its customers' needs and to improve its market position. See further details in Note 5 below and Notes 12B, 16A(3) and 17F-J to the 2008 audited consolidated financial statements.

The worldwide economic downturn that commenced in 2008 and its effect on the semiconductor industry resulted in global decreased demand, downward price pressure, excess inventory and unutilized capacity worldwide. While many market analysts and others report signs of recovery, there is no assurance that markets will sufficiently recover the effect of the downturn. A lack of or slower than expected market recovery may adversely affect the future financial results and position of the Company, including its ability to fulfill its debt obligations and other liabilities and support its growth. The Company is taking several measures in order to mitigate the potential effect of this downturn, including fund-raisings, sale of fixed assets and/or intellectual property licensing, possible sale and lease-back of a portion of real estate assets, and the receipt of all or part of pending grants from the Israeli Investment Center. There is no assurance that the Company will be able to obtain sufficient funding from these or other sources to allow it to have sufficient cash to fulfill its debt obligations and other liabilities and support its growth plans. See also Notes 12B, 16A(3), 16A(6) and 17 F-J to the 2008 audited consolidated financial statements.

#### NOTE 2 - INVENTORIES

Inventories consist of the following:

	September 30, 2009			December 31, 2008			
Raw materials	\$	7,526	\$	13,673			
Work in process		18,777		13,966			
Finished goods		2,443		13,260			
	\$	28,746	\$	40,899			

Work in process and finished goods inventories are presented net of aggregate write downs to net realizable value of \$3,037 and \$12,488 as of September 30, 2009 and December 31, 2008, respectively.

(dollars in thousands, except share data and per share data)

#### NOTE 2 - INVENTORIES (cont.)

Following the Jazz Merger, Tower and Jazz have been working to align their reporting and information systems. During 2009, the process was concluded with Jazz adopting in its financial statements the same method of calculating the cost of inventories used by Tower. The primary result of such adoption is the inclusion of depreciation and amortization as part of the cost of inventory. In addition, indirect raw material that had been previously immediately charged in Jazz to earnings, is now being capitalized and presented as part of raw material inventory of Jazz until it is consumed. Comparative financial statements of prior periods (in which Jazz was consolidated) have been adjusted to apply the new method retrospectively. The following financial statement line items for fiscal year 2008 were affected by the change in accounting principle.

#### As of December 31, 2008:

	As or	iginally reported	As	adjusted	Effec	ct of change
Inventories	\$	38,729	\$	40,899	\$	2,170
Shareholders' Equity	\$	110,277	\$	112,447	\$	2,170

#### NOTE 3 - PRO-FORMA FINANCIAL INFORMATION

The following unaudited pro-forma financial information assumes that the Jazz Merger occurred on January 1, 2008. Such information is presented for illustrative purposes only and is not necessarily indicative of the operating results that would have been achieved if the Jazz Merger had taken place on the date specified, nor are they indicative of the Company's future operating results.

	ended	ne months I September 0, 2008
Revenues	\$	306,591
Loss		(84,546)
Loss per share - basic and diluted	\$	(0.53)

See additional business and financial information regarding the Jazz Merger in Note 3 to the 2008 consolidated financial statements.

#### NOTE 4 - FAIR VALUE MEASUREMENTS

#### (A) Fair Value of Financial Instruments

The estimated fair values of the Company's financial instruments, excluding the Company's long-term debentures and long-term banks loans, do not materially differ from their respective carrying amounts as of September 30, 2009 and December 31, 2008. The fair values of Tower and Jazz's debentures, based on quoted market prices as of September 30, 2009 and December 31, 2008 were \$215,350 and \$60,264, respectively.

(dollars in thousands, except share data and per share data)

#### NOTE 4 - FAIR VALUE MEASUREMENTS (cont.)

#### (B) Fair Value Measurements

Fair values were determined using the income approach using a present value technique, as follows:

For Tower's loans - the cash flows used in the technique reflect the cash stream expected to be used to satisfy the obligation over its economic life. The Company discounted expected cash flows as forecasted each quarter using the appropriate discount rate for the applicable maturity.

For embedded derivatives - the Company utilized the Black Scholes Merton formula.

For over the counter derivatives - the Company used the market approach using quotation from independent brokers and dealers.

For Tower's convertible debentures series E - the market approach using quoted market prices was used.

Recurring Fair Value Measurements Using the Indicated Inputs:

			Quoted prices in active market for		Significant other observable			gnificant bservable		
	September identical liability		September		mber identical liability			inputs		inputs
	30, 2009		(Level 1)		(Level 1)		(I	Level 2)	(	level 3)
Convertible debentures series E	\$	34,149	\$	34,149	\$		\$			
Tower's Long-term debt		164,687						164,687		
Derivatives		3,478				3,478				
Warrants and previously bifurcated										
conversion option		14,378		1,181				13,197		
	\$	216,692	\$	35,330	\$	3,478	\$	177,884		

(dollars in thousands, except share data and per share data)

#### NOTE 4 - FAIR VALUE MEASUREMENTS (cont.)

#### (B) Fair Value Measurements (cont.)

Liabilities measured on a recurring basis using significant unobservable inputs (Level 3):

	L	ong-term debt	•			rrants and eviously furcated rsion option
As of January 1, 2009 - at fair value	\$	202,989	\$	16,825	\$	
Reclassification of warrants and previously bifurcated conversion option from equity to liability - see Note 1A(3) - Initial Adoption of New Standards - ASC 815-40-15						89
Total losses (gains) unrealized in earnings		(38,302)		5,922		13,108
Transfer out of Level 3				(22,747)		
As of September 30, 2009 - at fair value	\$	164,687	\$		\$	13,197
Unrealized losses (gains) in earnings from liabilities held at period end	\$	(38,302)	\$	5,922	\$	13,108

Recurring Fair Value Measurements Using the Indicated Inputs:

	Dec	cember 31, 2008	active identi	ed prices in market for cal liability evel 1)	_	nificant other ervable inputs (Level 2)	1	Significant unobservable inputs (Level 3)
Convertible debentures series E	\$	16,825	\$		\$		\$	16,825
Tower's long-term debt		202,989						202,989
Derivatives		3,236				3,236		
	\$	223,050	\$		\$	3,236	\$	219,814

#### (C) Composition of Balances

As of September 30, 2009 and December 31, 2008 long-term loans from Banks amounted to \$184,687 and \$222,989, respectively, of which \$164,687 and \$202,989 at fair value as of such dates.

As of September 30, 2009 and December 31, 2008 debentures amounted to \$231,868 and \$208,512, respectively, of which \$31,907 and \$16,825 at fair value as of such dates.

(dollars in thousands, except share data and per share data)

#### NOTE 5 - RECENT DEVELOPMENTS

#### A. The Israel Corporation Investment

As part of the September 2008 definitive agreements with the Banks and The Israel Corporation ("TIC"), detailed in Notes 12B and 16A(3) to the 2008 audited consolidated financial statements, TIC invested \$20,000 in the Company in January 2009. In consideration, Tower issued TIC equity equivalent capital notes convertible into approximately 77 million of Tower's ordinary shares. These equity equivalent capital notes have no voting rights, no maturity date, no dividend rights, are not tradable, are not registered, do not carry interest, are not linked to any index and are not redeemable.

#### B. Share Incentive Plan for the Chairman of the Board of Directors

In June 2009, the audit committee of the Company's board of directors (the "Audit Committee") and the Company's board of directors ("Board") approved a grant to the new Chairman of the Board of options to purchase 11.5 million ordinary shares of the Company. Said grant is subject to the approval of the shareholders of the Company. The date of grant shall be the date the shareholders of the Company will approve said grant (the "Date of Grant"). The exercise price is \$0.29 (but not lower than the nominal value of the Company's ordinary shares), which was the closing price of the Company's ordinary shares on the NASDAQ Global Market on the trading day immediately prior to the date of approval of the grant by the Board. The options vest over three years as follows: 50% of the options shall vest on the second anniversary of the Date of Grant and an additional 50% on the third anniversary of the Date of Grant. The options are exercisable for a period of seven years from the Date of Grant.

(dollars in thousands, except share data and per share data)

#### NOTE 5 - RECENT DEVELOPMENTS (cont.)

#### C. Share Incentive Plan for the Company's Employees and CEO

In November 2008, the Audit Committee and Board approved the Company's 2009 Employee Share Incentive Plan (the "Plan") to grant options and/or restricted share units ("RSU's") to the Company's employees (including its CEO) and to the employees of the Company's subsidiaries, which plan was approved by the Company's shareholders in April 2009. Up to approximately 28 million options are reserved for grant to the Company's employees and its subsidiaries' employees (excluding its CEO), and an additional approximately 28 million options under the Plan are reserved for grant to the Company's CEO. However, the amount of available options for grant at any time will be reduced by the aggregate number of outstanding options available for grant under previous employee option plans and under the previous CEO Share Option Plan. In June 2009, the Company's Board approved a grant to the Company's CEO under the Plan to purchase up to 8.5 million ordinary shares. These options are exercisable at an exercise price of \$0.29 (but not lower than the nominal value of the Company's ordinary shares), which was the closing price of the Company's shares on the NASDAO Global Market on the trading day immediately prior to the date of approval of the grant by the Board. These options will vest over a three-year period as follows: 50% of the options shall vest on the second anniversary of the date of grant and an additional 50% on the third anniversary of the date of grant. The options granted are exercisable for a period of seven years from the date of grant. In June 2009, the Board approved a grant to the employees of the Company under the Plan to purchase up to 9 million ordinary shares. These options are exercisable at an exercise price of \$0.29 (but not lower than the nominal value of the Company's ordinary shares), which was the closing price of the Company's shares on the NASDAQ Global Market on the trading day immediately prior to the date of approval of the grant by the Board. These options will vest over a three-year period as follows: 50% of the options shall vest on the second anniversary of the date of grant and an additional 50% on the third anniversary of the date of grant. The options granted are exercisable for a period of seven years from the date of grant.

#### **D.** Options Granted to Directors

During 2009, under the Company's Independent-Director Share Option Plan, 0.3 million options were granted to new directors appointed to the Board in 2009 at an average exercise price of \$0.20 (but not lower than the nominal value of the Company's ordinary shares).

(dollars in thousands, except share data and per share data)

#### NOTE 5 - RECENT DEVELOPMENTS (cont.)

#### E. Securities Price Adjustments

The convertible debentures series E and the warrants series 6, which were issued in 2007, were convertible into Tower's ordinary shares at a conversion price of NIS 17.2 and \$2.04, respectively. The conversion prices were subject to adjustments under certain limited circumstances during a two year period. Under such circumstances, the conversion price for convertible debentures series E was reduced from NIS 17.2 to NIS 4.15 and for warrants series 6 from \$2.04 to \$1.06. Convertibles debentures series E are carried at fair value through profit and loss and the effect of the reduction in conversion price was reflected in the mark to market of the convertibles. Warrants series 6 were carried at fair value due to the existence of the ratchet described above according to the provisions of ASC 815-40-15. After the exercise price was adjusted and the ratchet expired the warrants were adjusted to fair value through earnings and reclassified to equity, since no future variability in the exercise price can occur. In addition, Warrants series I, which were issued in 2007, were exercisable into Tower's ordinary shares at an exercise price of \$2.04. This exercise price is subject to an adjustment mechanism under certain limited circumstances during a five year period. Under such circumstances, the adjusted exercise price, as of September 30, 2009 and as of the approval date of the financial statements, is \$0.74. Since Tower's warrants series I are carried at fair value, the changes in fair value reflect the decreased exercise price. Warrants series I will continue to be carried at fair value due to potential exercise price adjustment.

#### F. Agreement with Crocus Technology

In June 2009, Tower and Crocus Technology, a premier developer of Magnetic Random Access Memory (MRAM), entered into an agreement to port Crocus' MRAM process technology into Tower's manufacturing environment. As part of the exclusive agreement, Tower will perform all manufacturing steps required for Crocus' next-generation MRAM technology in Fab2. In addition to collaborating on the process port, Tower will receive an equity position in Crocus valued at \$1,250.

#### G. Agere/LSI Action

During 2008, an International Trade Commission ("ITC") action was filed by Agere/LSI Corporation ("LSI"), which alleged infringement by 17 corporations of LSI's patent No. 5227335. Following the initial filing, LSI amended the ITC complaint to add Tower, Jazz and three other corporations as additional respondents. Tower, Jazz and the other three corporations were added as additional respondents in the ITC action in October 2008. The case was tried before an administrative law judge ("Judge") in July 2009. In September 2009, the Judge ruled against LSI and in favor of the respondents, determining that the patent claims asserted by LSI are invalid. LSI has filed a Petition for Review, seeking a reversal of the Judge's decision.

(dollars in thousands, except share data and per share data)

#### NOTE 5 - RECENT DEVELOPMENTS (cont.)

#### H. Banks Facility Agreement

During 2009, the Banks and Tower entered into an amendment to the Facility Agreement to: (i) postpone the repayment schedule of the outstanding loans, to be repaid in 8 equal quarterly installments from September 2011 until June 2013; (ii) waive the financial covenants stipulated in the Facility Agreement through December 31, 2009. Since the loans are carried at fair value, the fair value as of September 30, 2009 includes the effects of the amendment. Upon certain circumstances, as stipulated in the amendment, and following receipt by Tower of significant amounts of proceeds from certain sources, Tower will pay a portion of such proceeds on account of the outstanding loans prior to the due date specified above. As part of the terms of the amendment, Tower agreed to extend the Banks' existing warrants to June 2013, issue the Banks new warrants in three annual tranches of \$1,000 each, at a quantity and price to be determined based on the future stock price (the first tranche of which was issued for an exercise price of \$0.89) and pay the Banks fees in the aggregate amount of \$350. The cost of the new warrants (all three tranches) and the additional cost of the existing warrants, which is determined based on the fair value at the date of the amendment, was expensed and recorded in financing expenses, as they relate to an item carried at fair value.

#### I. Definitive Agreement with YA Global Master SPV Ltd

In August 2009, Tower entered into a definitive agreement with YA Global Master SPV Ltd. ("Yorkville"), according to which Yorkville committed to invest in Tower, subject to a request from Tower, up to \$25,000 over the next 24 months by way of a stand-by equity-line, in consideration for ordinary shares of Tower to be issued at a 3% discount to the market price of the ordinary shares as determined in accordance with the agreement. Investment made by Yorkville will be made such that Yorkville will not hold more than 4.99% of Tower's ordinary shares during the period of the agreement. As of September 30, 2009, draw downs in the amount of \$2,150 have been made under this agreement. No warrants or any debt or derivative instruments were issued by Tower under this agreement.

#### J. Investment by Israeli Institutional Investors

In September 2009, certain Israeli institutional investors invested approximately \$21,100 of gross proceeds in Tower's shareholders' equity. In consideration for such investment, Tower sold approximately 22 million ordinary shares ("Shares") and approximately 5.3 million Warrants Series 6 ("Warrants"). The Warrants are exercisable through August 2011, are traded on the Tel Aviv Stock Exchange, and are classified in shareholders' equity.

#### MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL

#### CONDITION AND RESULTS OF OPERATIONS

The information contained in this section should be read in conjunction with (1) our unaudited condensed interim consolidated financial statements as of September 30, 2009 and for the nine months then ended and related notes included in this report and (2) our consolidated financial statements and related notes included in our Annual Report on Form 20-F for the year ended December 31, 2008 and the other information contained in such Annual Report, particularly the information in Item 5- "Operating and Financial Review and Prospects". Our financial statements have been prepared in accordance with generally accepted accounting principles in United States ("US GAAP").

Following the Company's merger with Jazz Technologies Inc. ("Jazz") on September 19, 2008, (the "Jazz Merger"), the Company's financial statements include Jazz results commencing September 19, 2008. The balance sheets as of September 30, 2009 and December 31, 2008 include Jazz's balances as of such dates.

#### **Results of Operations**

The following table sets forth certain statement of operations data as a percentage of total revenues for the periods indicated.

	Nine Months Ended September 30,		
	2009	2008	
<b>Statement of Operations Data:</b>			
Revenues	100%	100%	
Cost of revenues	116.7	120.8	
Gross loss	(16.7)	(20.8)	
Research and development expenses, net	8.3	5.6	
Marketing, general and administrative expenses	11.1	13.0	
Write-off of in-process research and development		1.3	
Merger related costs		0.3	
Fixed assets impairment		69.2	
Operating loss	(36.0)	(110.2)	
Financing expense, net	(13.6)	(11.7)	
Gain on debt restructuring		75.0	
Other income (expenses), net	1.1	(0.4)	
Income tax benefit	3.6		
Loss for the period	(44.9)%	(47.2)%	

#### Nine Months Ended September 30, 2009 compared to the Nine Months Ended September 30, 2008

*Revenue*. Revenue for the nine months ended September 30, 2009 amounted to \$198.2 million compared to \$174.2 million for the nine months ended September 30, 2008.

Revenues for the nine months ended September 30, 2009 increased by 13.8% as compared to the corresponding period in 2008, due to the inclusion of the revenues of Jazz for the nine months ended September 30, 2009 of \$105.0 million as compared to \$8.6 million in the nine months ended September 30, 2008.

Cost of Total Revenues. Cost of total revenues for the nine months ended September 30, 2009 amounted to \$231.2 million, as compared to \$210.4 million for the nine months ended September 30, 2008. This 9.9% increase in cost of revenues resulted from the inclusion of the costs of Jazz for the nine months ended September 30, 2009 (as compared to including the costs of Jazz in the cost of revenues only as of the date of the Jazz Merger in the corresponding period in 2008), which was partially offset by the cost reduction plan executed by the Company and synergies captured through the integration of Jazz.

*Gross Loss*. Gross loss for the nine months ended September 30, 2009 was \$33.1 million compared to a gross loss of \$36.2 million for the nine months ended September 30, 2008. The decrease in gross loss was mainly attributable to the 13.8% increase in revenues which was partly offset by the 9.9% increase in cost of total revenues as described above.

Research and Development. Research and development expenses for the nine months ended September 30, 2009 amounted to \$16.4 million as compared to \$9.7 million for the nine months ended September 30, 2008. This increase in research and development costs is a result of the inclusion of the costs of Jazz for the nine months ended September 30, 2009 (as compared to including the costs of Jazz only as of the date of the Jazz Merger in the corresponding period in 2008), which was partially offset by the cost reduction plan executed by the Company and synergies captured through the integration of Jazz.

Marketing, General and Administrative Expenses. Marketing, general and administrative expenses for the nine months ended September 30, 2009 amounted to \$21.9 million as compared to \$22.7 million for the nine months ended September 30, 2008. Such decrease in marketing, general and administrative expenses, which also includes the results of Jazz for the nine months ended September 30, 2009, is mainly attributed to the cost reduction plan executed by the Company and synergies captured through the integration of Jazz.

Fixed Assets Impairment. Fixed assets impairment amounted to \$120.5 million in the nine months ended September 30, 2008. The worldwide economic downturn and the adverse market conditions in the semiconductor industry that commenced in 2008, resulted in global decreased demand, downward price pressure, excess inventory and unutilized capacity worldwide. As a result, we determined in 2008 that the circumstances indicate that the carrying amount may not be recoverable. In accordance with SFAS No. 144 "Accounting for the Impairment or Disposal of Long-Lived Assets", we tested the recoverability of our plant and equipment based, among others, on our business plan and market prevailing conditions and determined that the carrying amounts of our plant and equipment may not be recoverable. We evaluated the fair value of our plant and equipment and determined that the carrying amounts exceed the fair values by \$120.5 million and recorded a charge in that amount in the nine months ended September 30, 2008.

Operating Loss. Operating loss for the nine months ended September 30, 2009 was \$71.3 million, compared to \$192.0 million for the nine months ended September 30, 2008. The decrease in the operating loss is mainly due to the one-time fixed assets impairment (as described above) in the nine months ended September 30, 2008. The amount of operating loss, excluding any one-time items in 2008, (which are comprised of \$120.5 fixed assets impairment and \$2.8 million write off of in process research and development and merger related costs), increased by \$2.7 million as compared to the nine months ended September 30, 2008. Such increase, despite including the costs of Jazz for the nine months ended September 30, 2009 (as compared to including the costs of Jazz only as of the date of the Jazz Merger in the corresponding period in 2008) is mainly attributed to the cost reduction plan executed by the Company and synergies captured through the integration of Jazz.

Financing Expenses, Net. Financing expenses, net for the nine months ended September 30, 2009 were \$27.0 million compared to financing expenses, net of \$20.4 million for the nine months ended September 30, 2008. Such increase is mainly due to the additional expenses related to Jazz's convertible notes which are included in the nine months ended September 30, 2009, offset partially by the lower interest due to lower principal following the definitive agreements with the Banks and the Israel Corp. ("TIC") executed in September 2008.

*Gain On Debt Restructuring.* Gain on debt restructuring in the nine months ended September 30, 2008 resulted from the definitive agreements with the Banks and TIC executed in September 2008, amounting to \$130.7 million in the nine months ended September 30, 2008.

*Income Tax Benefit.* Income Tax Benefit amounted to \$7.2 million in the nine months ended September 30, 2009 and are in relation to Jazz business.

Loss. Loss for the nine months ended September 30, 2009 was \$89.0 million as compared to \$82.3 million for the nine months ended September 30, 2008. This increase is mainly attributed to the \$130.7 million of gain on debt restructuring in the nine months ended September 30, 2008 and the \$6.7 million increase in financing expense, net (as described above), which was partially offset by the \$120.6 million of lower operating loss and \$7.2 million income tax benefit in the nine months ended September 30, 2009 (as described above).

#### **Impact of Inflation and Currency Fluctuations**

The US Dollar costs of our operations in Israel are influenced by changes in the rate of inflation in Israel and the extent to which such changes are not offset by the change in valuation of the NIS in relation to the US Dollar. During the nine months ended September 30, 2009, the exchange rate of the US Dollar in relation to the NIS decreased by 1.2% and the Israeli Consumer Price Index ("CPI") increased by 3.4% (during the nine months ended September 30, 2008 there was a decrease of 11.0% in the exchange rate of the US Dollar in relation to the NIS and an increase of 4.4% in the CPI).

We believe that the rate of inflation in Israel did not have a material effect on our business to date. However, our US Dollar costs will increase if inflation in Israel exceeds the devaluation of the NIS against the US Dollar, or if the timing of such devaluation will be following inflation in Israel.

Nearly the entire cash generated from our operations and from our financing and investing activities is denominated in US Dollar and NIS. Our expenses and costs are denominated in NIS, US Dollar, Japanese Yen and Euros. We are, therefore, exposed to the risk of currency exchange rate fluctuations.

#### **Liquidity and Capital Resources**

As of September 30, 2009, we had an aggregate amount of \$51.7 million in cash and cash equivalents, as compared to \$34.9 million as of December 31, 2008.

During the nine months ended September 30, 2009, we raised \$ 22.2 million through issuance of shares and warrants (for further details see Notes 5I-J to the unaudited condensed interim consolidated financial statements as of September 30, 2009), \$20.0 million through capital notes in connection with a TIC investment (for further details see Notes 5A to the unaudited condensed interim consolidated financial statements as of September 30, 2009) and generated a net amount of \$7.9 million from our operating activities. These liquidity resources financed the capital investments we made during the nine months ended September 30, 2009, which aggregated to an amount of \$19.2 million and the repayment of debentures and other debt in the total amount of \$14 million.

As of September 30, 2009, the Company's loans from banks were presented under GAAP in the amount of \$189.1 million, of which \$4.4 million are presented as short-term. As of such date, we presented an aggregate of \$231.9 million of debentures in our balance sheet (under GAAP). See also Note 1B to the unaudited condensed interim consolidated financial statements as of September 30, 2009.